呼吸指南

订阅

MedSci主页 / 所有栏目 / 呼吸指南

NICE指南：减少新冠肺炎患者静脉血栓栓塞风险

2021-02-01 国家卫生和护理研究所（NICE） NICE

新冠肺炎

该指南涵盖了接受COVID-19肺炎治疗的患者的药理性VTE预防。 它包括在医院或社区环境中接受治疗的患者，例如“在家医院”服务或COVID-19“虚拟病房&rdq

中文标题：

NICE指南：减少新冠肺炎患者静脉血栓栓塞风险

英文标题：

COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19

发布机构：

国家卫生和护理研究所（NICE）

发布日期：

2021-02-01

简要介绍：

该指南涵盖了接受COVID-19肺炎治疗的患者的药理性VTE预防。 它包括在医院或社区环境中接受治疗的患者，例如“在家医院”服务或COVID-19“虚拟病房”。 该指南适用于所有COVID-19肺炎患者，包括患有其他疾病的患者。

相关资料下载：
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=ef7e11c00205598c, title=NICE指南：减少新冠肺炎患者静脉血栓栓塞风险, enTitle=COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19, guiderFrom=NICE, authorId=0, author=, summary=该指南涵盖了接受COVID-19肺炎治疗的患者的药理性VTE预防。 它包括在医院或社区环境中接受治疗的患者，例如“在家医院”服务或COVID-19“虚拟病房&rdq, cover=, journalId=0, articlesId=null, associationId=1435, associationName=国家卫生和护理研究所（NICE）, associationIntro=, copyright=0, guiderPublishedTime=Mon Feb 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span class="VIiyi" lang="zh-CN"><span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="0">该指南涵盖了接受COVID-19肺炎治疗的患者的药理性VTE预防。</span> <span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="1">它包括在医院或社区环境中接受治疗的患者，例如&ldquo;在家医院&rdquo;服务或COVID-19&ldquo;虚拟病房&rdquo;。</span> <span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="2">该指南适用于所有COVID-19肺炎患者，包括患有其他疾病的患者。</span></span></p>, tagList=[TagDto(tagId=99273, tagName=新冠肺炎)], categoryList=[CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=38, categoryName=急重症科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=13734, appHits=116, showAppHits=0, pcHits=475, showPcHits=13618, likes=1, shares=6, comments=10, approvalStatus=1, publishedTime=Sat Feb 13 19:38:06 CST 2021, publishedTimeString=2021-02-01, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Sat Feb 13 19:38:02 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Thu Jan 04 20:11:56 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击：
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=969978, encodeId=9b579699e8ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d47b5510628, createdName=胡雪琴, createdTime=Tue Jun 01 00:11:11 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966558, encodeId=424a966558c4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c3c1692607, createdName=心愿依在, createdTime=Tue May 18 13:26:48 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960960, encodeId=61fe9609609e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/10/f6f1f6ef2f0f4f5eb8d6b9f97243bb3f.jpg, createdBy=c5102133863, createdName=gujun830412, createdTime=Tue Apr 27 15:20:52 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951664, encodeId=17db9516648d, content=能给予一定的参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=475c5473813, createdName=ms1000001690948493, createdTime=Sat Mar 27 18:30:57 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953070, encodeId=fa1a9530e050, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42245448959, createdName=ms7000000261672610, createdTime=Thu Apr 01 15:12:56 CST 2021, time=2021-04-01, status=1, ipAttribution=)]
    2021-06-01 胡雪琴

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=969978, encodeId=9b579699e8ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d47b5510628, createdName=胡雪琴, createdTime=Tue Jun 01 00:11:11 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966558, encodeId=424a966558c4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c3c1692607, createdName=心愿依在, createdTime=Tue May 18 13:26:48 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960960, encodeId=61fe9609609e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/10/f6f1f6ef2f0f4f5eb8d6b9f97243bb3f.jpg, createdBy=c5102133863, createdName=gujun830412, createdTime=Tue Apr 27 15:20:52 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951664, encodeId=17db9516648d, content=能给予一定的参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=475c5473813, createdName=ms1000001690948493, createdTime=Sat Mar 27 18:30:57 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953070, encodeId=fa1a9530e050, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42245448959, createdName=ms7000000261672610, createdTime=Thu Apr 01 15:12:56 CST 2021, time=2021-04-01, status=1, ipAttribution=)]
    2021-05-18 心愿依在

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=969978, encodeId=9b579699e8ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d47b5510628, createdName=胡雪琴, createdTime=Tue Jun 01 00:11:11 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966558, encodeId=424a966558c4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c3c1692607, createdName=心愿依在, createdTime=Tue May 18 13:26:48 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960960, encodeId=61fe9609609e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/10/f6f1f6ef2f0f4f5eb8d6b9f97243bb3f.jpg, createdBy=c5102133863, createdName=gujun830412, createdTime=Tue Apr 27 15:20:52 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951664, encodeId=17db9516648d, content=能给予一定的参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=475c5473813, createdName=ms1000001690948493, createdTime=Sat Mar 27 18:30:57 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953070, encodeId=fa1a9530e050, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42245448959, createdName=ms7000000261672610, createdTime=Thu Apr 01 15:12:56 CST 2021, time=2021-04-01, status=1, ipAttribution=)]
    2021-04-27 gujun830412

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=969978, encodeId=9b579699e8ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d47b5510628, createdName=胡雪琴, createdTime=Tue Jun 01 00:11:11 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966558, encodeId=424a966558c4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c3c1692607, createdName=心愿依在, createdTime=Tue May 18 13:26:48 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960960, encodeId=61fe9609609e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/10/f6f1f6ef2f0f4f5eb8d6b9f97243bb3f.jpg, createdBy=c5102133863, createdName=gujun830412, createdTime=Tue Apr 27 15:20:52 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951664, encodeId=17db9516648d, content=能给予一定的参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=475c5473813, createdName=ms1000001690948493, createdTime=Sat Mar 27 18:30:57 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953070, encodeId=fa1a9530e050, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42245448959, createdName=ms7000000261672610, createdTime=Thu Apr 01 15:12:56 CST 2021, time=2021-04-01, status=1, ipAttribution=)]
    2021-03-27 ms1000001690948493

    能给予一定的参考

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=969978, encodeId=9b579699e8ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d47b5510628, createdName=胡雪琴, createdTime=Tue Jun 01 00:11:11 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966558, encodeId=424a966558c4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c3c1692607, createdName=心愿依在, createdTime=Tue May 18 13:26:48 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960960, encodeId=61fe9609609e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/10/f6f1f6ef2f0f4f5eb8d6b9f97243bb3f.jpg, createdBy=c5102133863, createdName=gujun830412, createdTime=Tue Apr 27 15:20:52 CST 2021, time=2021-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951664, encodeId=17db9516648d, content=能给予一定的参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=475c5473813, createdName=ms1000001690948493, createdTime=Sat Mar 27 18:30:57 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953070, encodeId=fa1a9530e050, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42245448959, createdName=ms7000000261672610, createdTime=Thu Apr 01 15:12:56 CST 2021, time=2021-04-01, status=1, ipAttribution=)]
    2021-04-01 ms7000000261672610

    好好学习

    0

相关指南

NICE维生素D在新冠肺炎中应用指南

国家卫生和护理研究所（NICE） · 2021-02-01

NICE新冠肺炎长期症状管理指南（NG188）

国家卫生和护理研究所（NICE） · 2020-12-18

美国新冠肺炎治疗指南2020

美国国家卫生研究院(NIH,The National Institutes of Health) · 2020-09-01

COVID-19患者的化学预防，诊断，治疗和出院管理：循证临床实践指南（更新版本）

中国医院协会(CHA,Chinese Hospital Association) ·

WHO治疗新冠肺炎药物动态指南

世界卫生组织(WHO,The World Health Organization) · 2020-09-15

新冠肺炎期间/后开展心衰临床试验专家共识2020

欧洲心力衰竭协会(HFA,Heart Failure Association) · 2020-06-12